Literature DB >> 9620326

Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

O N El-Assal1, A Yamanoi, Y Soda, M Yamaguchi, M Igarashi, A Yamamoto, T Nabika, N Nagasue.   

Abstract

As in other tumors, the assessment of microvessel density (MVD) in hepatocellular carcinoma (HCC) may be essential to perform an effective anti-angiogenic therapy for this tumor. The relationship between vascular endothelial growth factor (VEGF) and MVD of HCC as well as the surrounding liver remains to be elucidated. In 71 patients who had undergone curative hepatic resection for HCC, MVD and VEGF expressions were evaluated for HCC and the liver by quantitative reverse-transcription polymerase chain reaction (RT-PCR) and/or immunostaining. The intensity and extent of VEGF immunoreactivity were evaluated using a computer image analyzer-cell analysis system (CAS). Angiographic data were re-evaluated and compared with MVD in 50 tumors. Tumoral MVD was significantly correlated with tumor capsule formation (t test, P = .0016). Small HCCs (< or = 2 cm) had a significantly lower MVD compared with moderate-sized HCCs (2-5 cm) (t test, P = .016), and the MVD of large HCCs was relatively lower than that of moderate tumors. Tumor vascularity on angiography was not correlated with the MVD. Neither VEGF mRNA levels nor protein expression in HCC were correlated with the tumoral MVD or any histopathological features of the tumor. However, cirrhotic livers had significantly higher MVD and VEGF expressions compared with noncirrhotic livers (t test, P = .0015 and P = .047, respectively). Only the MVD of tumor was significantly correlated with intrahepatic recurrence (t test, P = .0048) and disease-free survival (DFS) rates (log rank test, P = .0035). Moreover, the MVD was an independent predictor for DFS by multivariate analysis (chi2 test, P = .03). In conclusion, the MVD in HCC may be involved in the dismal prognosis of this tumor, and VEGF may be associated with the angiogenic process of the cirrhotic liver, but not with the angiogenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620326     DOI: 10.1002/hep.510270613

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  95 in total

1.  High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients.

Authors:  Jian-Cong Sun; Xiao-Ting Liang; Ke Pan; Hui Wang; Jing-Jing Zhao; Jian-Jun Li; Hai-Qing Ma; Yi-Bing Chen; Jian-Chuan Xia
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

2.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

Review 3.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

4.  Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment.

Authors:  Amitava Das; Uday Shergill; Lokendra Thakur; Sutapa Sinha; Raul Urrutia; Debabrata Mukhopadhyay; Vijay H Shah
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-25       Impact factor: 4.052

5.  Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues.

Authors:  Geertu Deli; Can-Hao Jin; Rong Mu; Song Yang; Yue Liang; De Chen; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

6.  Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).

Authors:  Hisashi Hidaka; Namiki Izumi; Takeshi Aramaki; Masafumi Ikeda; Yoshitaka Inaba; Kazuho Imanaka; Takuji Okusaka; Susumu Kanazawa; Shuichi Kaneko; Shinichi Kora; Hiroya Saito; Junji Furuse; Osamu Matsui; Tatsuya Yamashita; Osamu Yokosuka; Satoshi Morita; Hitoshi Arioka; Masatoshi Kudo; Yasuaki Arai
Journal:  Med Oncol       Date:  2019-05-03       Impact factor: 3.064

Review 7.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

8.  Angiogenesis effect on rat liver after administration of expression vector encoding vascular endothelial growth factor D.

Authors:  Bao-Min Shi; Xiu-Yan Wang; Qing-Ling Mu; Tai-Huang Wu; Hong-Jun Liu; Zhen Yang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease.

Authors:  Nicole L Ward; Alexandra L Haninec; Paul Van Slyke; John G Sled; Celina Sturk; R Mark Henkelman; Ian R Wanless; Daniel J Dumont
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics.

Authors:  Wenjiao Zeng; Annette S H Gouw; Marius C van den Heuvel; Grietje Molema; Sibrand Poppema; Eric J van der Jagt; Koert P de Jong
Journal:  Ann Surg Oncol       Date:  2010-01-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.